- Home
- NVNI vs RFL Comparison
NVNI vs RFL Comparison
Compare NVNI & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NVNI | RFL |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | | Real Estate |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.2M | 54.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NVNI | RFL |
|---|---|---|
| Price | $3.92 | $1.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 150.9K | 92.7K |
| Earning Date | 09-30-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,250,627.00 | $917,000.00 |
| Revenue This Year | $12.05 | N/A |
| Revenue Next Year | $15.02 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1491.58 | 43.96 |
| 52 Week Low | $1.44 | $1.17 |
| 52 Week High | $121.90 | $3.19 |
Technical Indicators
Market Signals| Indicator | NVNI | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 69.09 | 43.20 |
| Support Level | $2.80 | $1.20 |
| Resistance Level | $3.00 | $1.29 |
| Average True Range (ATR) | 0.27 | 0.06 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 89.73 | 50.00 |
Price Performance
Historical ComparisonAbout NVNI Nvni Group Limited
Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.